Gene signature profiling of gynaecological malignancies

被引：1

作者：

Horak P. ^{[1
]}

机构：

[1] Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18–20, Vienna

来源：

memo - Magazine of European Medical Oncology | 2014年 / 7卷 / 4期

关键词：

Biomarkers; Cervical cancer; Endometrial cancer; Gene expression profiling; Gene signatures; Molecular subtypes; Ovarian cancer; Prognostic factors;

D O I：

10.1007/s12254-014-0177-1

中图分类号：

学科分类号：

摘要：

Genetic profiling of cancer may lead to a better understanding of its intra- as well as intertumoural heterogeneity as well as targeted, patient-oriented cancer therapy. Due to the recent advances in molecular biology, important steps towards this goal have been accomplished. Among others, several large profiling analyses of gynaecologic malignancies have been completed and published recently. Most notably, these comprehensive molecular analyses expose a high degree of cancer complexity and heterogeneity. Integration of this data into clinical practice will result in new tumour classifications and possibly change our understanding of cancer pathogenesis and thus necessitate the development of novel diagnostic and therapeutic algorithms. © 2014, Springer-Verlag Wien.

引用

页码：252 / 255

页数：3

共 24 条

[1]

Gray S.W., Hicks-Courant K., Cronin A., Rollins B.J., Weeks J.C., Physiciansʼ attitudes about multiplex tumor genomic testing, J Clin Onco, 3, 13, pp. 1317-1323, (2014)

[2]

Gampenrieder S., Rinnerthaler G., Greil R., Multi-gene signatures in breast cancer: actual clinical impact, Mem, 7, 1, pp. 16-21, (2014)

[3]

Jemal A., Bray F., Center M.M., Global cancer statistics, CA Cancer J Cli, 61, 2, pp. 69-90, (2008)

[4]

Bast R.C., Hennessy B., Mills G.B., The biology of ovarian cancer: new opportunities for translation, Nat Rev Cance, 9, 6, pp. 415-428, (2009)

[5]

Bonome T., Lee J.Y., Park D.C., Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary, Cancer Re, 65, 22, pp. 10602-10612, (2005)

[6]

Zorn K.K., Bonome T., Gangi L., Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer, Clin Cancer Re, 11, 18, pp. 6422-6430, (2005)

[7]

Wiegand K.C., Shah S.P., Al-Agha O.M., ARID1A mutations in endometriosis-associated ovarian carcinomas, N Engl J Me, 363, 16, pp. 1532-1543, (2010)

[8]

Kim J., Coffey D.M., Creighton C.J., High-grade serous ovarian cancer arises from fallopian tube in a mouse model, Proc Natl Acad Sci U S , 109, 10, pp. 3921-3926, (2012)

[9]

Darcy K.M., Birrer M.J., Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies, Gynecol Onco, 117, 3, pp. 429-439, (2010)

[10]

Konstantinopoulos P.A., Spentzos D., Cannistra S.A., Gene-expression profiling in epithelial ovarian cancer, Nat Clin Pract Onco, 5, 10, pp. 577-587, (2008)

← 1 2 3 →